Current guidelines for the evaluation and management of atopic dermatitis: A comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines

Selected serum oxidative stress biomarkers in dogs with non‐food‐induced and food‐induced atopic dermatitis

“…The findings of this study suggest the presence of OS in the population of dogs with AD, both FIAD and NFIAD, and add further evidence that OS may be a factor in the pathogenesis of canine AD . In humans and dogs, AD is by definition an inflammatory and pruritic disease . In this context, it has been reported that OS can lead both to inflammation and pruritus.…”

First-in-human topical microbiome transplantation with Roseomonas mucosa for atopic dermatitis

“…While contemporary studies have elucidated how S. aureus may directly exacerbate AD (12), both topical and prophylactic antibiotics have failed to show benefit and are not recommended by any consensus management guidelines (1,13). We noted that in published microbiome studies the areas of skin characterized by carriage of Gram-negative bacteria (14) overlap with areas most commonly involved in AD (15), and this carriage is significantly decreased in AD patients compared with healthy controls (16).…”

“…Atopic dermatitis (AD) is a highly prevalent inflammatory skin disease associated with reduced quality of life, increased health care expenditures, and an increased risk of developing asthma, allergic rhinitis, and food allergies (1,2). The underlying pathology of AD includes impaired skin barrier function, susceptibility to Staphylococcus aureus skin infection, and immune dysregulation (3).…”

Therapeutic pipeline for atopic dermatitis: End of the drought?

“…For more severely affected subjects, systemically administered broad immunosuppressant drugs (cyclosporine, azathioprine, methotrexate, mycophenolate mofetil, and short courses of systemic corticosteroids) are used. 21 Topical steroid use has been associated with largely cutaneous adverse events, most often skin thinning (atrophy and striae). Systemic agents all have several drug-specific risks and broadly suppress the immune system.…”